Review
BibTex RIS Cite

Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein

Year 2019, Volume: 2 Issue: 1, 27 - 34, 31.01.2019

Abstract

Morbidite ve mortalite oranları her geçen gün artan endokrin bir bozukluk olan diabetes mellitus ve tedavisi üzerine günümüzde oldukça fazla araştırma yapılmaktadır. Ancak hala hastalığın çeşitli alt tiplerinin oluşum mekanizmaları ve bu mekanizmalara dahil olan proteinler ile bu proteinlerin sinyal yolakları tam olarak aydınlatılamamıştır. Tam olarak tedavisi mümkün olmayan bu hastalığın günümüz sedanter yaşam koşulları ve dengesiz beslenme sonucunda görülme sıklığı gün geçtikçe hızla artmaktadır. Bu anlamda hastalığın oluşum mekanizmasında etkin rol oynayan moleküller, proteinler ve bunların yolaklarının aydınlatılması, hastalığın tedavisinde yeni yaklaşımların oluşması için büyük bir önem arz etmektedir. Tiyoredoksin etkileşimli protein, son yıllarda keşfedilmiş olup, tip 1 ve tip 2 diabetes mellitusun patoenezinde önemli bir rol oynadığı düşünülmektedir.TXNIP eksikliği, pankreas beta hücrelerinin canlılığını destekleyerek, tip 1 ve tip 2 diabete karşı korurken, yükselen TXNIP seviyeleri beta hücreli apoptosise neden olmaktadır. Bu derlemede diabetes mellitus ve etiyopatogenezinde önemli bir rolü olan tiyoredoksin protein hakkında bilgi verilecektir.

References

  • 1. ADA, (2014). Clinical Practice Recommendations. Standards of Medical Care in Diabetes. Diabetes Care 37, 14-80.
  • 2. Alhawiti NM, Mahri SA, Aziz MA, Malik SS, Mohammad S, (2017). TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook. Current Drug Targets 18 (9),1095-1103.
  • 3. Artner I, Hang Y, Mazur M, (2010). MafA and MafB regulate genes critical to-cells in a unique temporal manner. Diabetes 59, 2530-2539.
  • 4. Bodnar JS, Chatterjee A, Castellani LW, (2002). Positional cloning of the combined hyperlipidemia gene Hyplip1. Nature Genetics 30, 110–116.
  • 5. Chen J, Fontes G, Saxena G, Poitout V, Shalev A, (2010). Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated -cell death. Diabetes 59, 440-447.
  • 6. Chen J, Hui ST, Couto FM, (2008). Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic ß cell mass and protects against diabetes. FASEB Journal 22, 3581-3594.
  • 7. Chen J, Jing G, Xu G, Shalev A, (2014). Thioredoxin-Interacting Protein Stimulates its Own Expression via a Positive Feedback Loop. Molecular Endocrinology 28, 674-680.
  • 8. Chen KS, DeLuca HF, (1994). Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochimica et Biophysica Acta 3, 1219-1226.
  • 9. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, Lee RT, (2010). Deletion of thealpha-arrestin protein Txnip in mice promotes adiposity and adipogenesiswhile preserving insulin sensitivity. Diabetes, 59, 1424-1434.
  • 10. Clee M, Nadler ST, Attie AD, (2005). Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. American Journal of Therapeutics 12, 491-498.
  • 11. Courboulin A, Paulin R, Giguère NJ, (2011). Role for miR-204 in human pulmonary arterial hypertension. Journal of Experimental Medicine 208, 535-548.
  • 12. Gül K, (2015). Diabetes mellitus sınıflama, tanı ve tarama testlerine genel bir bakış. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 10 (2), 12-16.
  • 13. IDF (International Diabetes Federation), (2013). Diabetes Atlas, 6th edition,
  • 14. Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A, (2014). Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through MIR-124A and FOXA2. Journal of Biological Chemistry 289, 11807-11815.
  • 15. Kibbe C, Chen J, Xu G, Jing G, Shalev A, (2013). FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic ß cells. Journal of Biological Chemistry 288, 23194-23202.
  • 16. Kumar V, Abbas AK, Aster JC, (2013). Robbins basic pathology (Robbins temel patoloji). Çeviren: Tuzlalı S, Güllüoğlu M, Çevikbaş U. Nobel Tıp Kitapevi, İstanbul.
  • 17. Minn A H, Hafele C, Shalev A, (2005). Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces ß-cell apoptosis. Endocrinology 146 (5), 2397-2405.
  • 18. Murray RK, Granner DK, Mayes PA, Rodewell VW, (2014). Harper’s Biochemistry. Çevirenler: Dikmen N, Özgüven T. Nobel Tıp Kitapevleri, Ankara.
  • 19. Oğuz A, (2016). Gestasyonel Diyabet. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 11 (1), 26-29.
  • 20. Özdemir İ, Hocaoğlu Ç, (2009). Tip 2 diabetes mellitus ve yaşam kalitesi: Bir gözden geçirme. Göztepe Tıp Dergisi 24 (2), 73-78.
  • 21. Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P, Jensen CB, (2007). TXNIP regulates peripheral glucose metabolism in humans. PLoS medicine 4 (5), e158.
  • 22. Patwari P, Chutkow W A, Cummings K, Verstraeten V L, Lammerding J, Schreiter E R, Lee R T, (2009). Thioredoxin-independent regulation of metabolism by the -arrestin proteins. Journal of Biological Chemistry 284 (37), 24996-25003.
  • 23. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT, (2006). The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. Journal of Biological Chemistry 281 (31), 21884-91.
  • 24. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S, (2011). Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. American Journal of Physiology-Heart and Circulatory Physiology 301, H1798-H1809.
  • 25. Reich E, Tamary A, Sionov RV, Melloul D, (2012). Involvement of thioredoxin- interacting protein (TXNIP) in glucocorticoid-mediated ß cell death. Diabetologia 55, 1048-1057.
  • 26. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J, (2013). Twelve-year trends in the prevalence and risk factors of diabetes and pre-diabetes in Turkish adults. European Journal of Epidemiology 28, 169-80.
  • 27. Saxena G, Chen J, Shalev A, (2010). Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. Journal of Biological Chemistry 285, 3997-4005.
  • 28. Shalev A, (2014). Minireview: Thioredoxin-Interacting Protein: Regulation and Function in the Pancreatic ß-Cell. Molecular Endocrinology 28, 1211-1220.
  • 29. Shalev A, Pise-Masison CA, Radonovich M, (2002). Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGF-ß signaling pathway. Endocrinology. 143, 3695-3698.
  • 30. Sönmez A, Kutlu M, (2010). Gestasyonel Diyabet Güncel Tarama ve Tanı Yöntemleri. Türkiye Klinikleri Endocrinology-Special Topics 3 (1), 1-5.
  • 31. Spindel ON, World C, Berk BC, (2012). Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxidants & Redox Signaling Journal 16, 587–596.
  • 32. Türkiye Endokrinoloji ve Metabolizma Derneği, (2018). Diabetes Mellitus Ve Komplikasyonlarının Tanı, Tedavi Ve İzlem Kılavuzu. Ankara, Tuna Matbaacılık, 8-11.
  • 33. Vila G, Gessl A W, Riedl M, Luger A, (2016). Other specific types of diabetes. Wiener klinische Wochenschrift 128, 208-211.
  • 34. Westermark P, Andersson A, Westermark GT, (2011). Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews 91, 795-826.
  • 35. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Kahn B. B, (2013). AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Molecular cell 49 (6), 1167-1175.
  • 36. Xu G, Chen J, Jing G, Shalev A, (2012). Preventing ß cell loss and diabetes with calcium channel blockers. Diabetes 61, 848-856.
  • 37. Xu G, Chen J, Jing G, Shalev A, (2013). Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nature Medicine 19, 1141-1146.
  • 38. Yamamoto M, Yamato E, Shu-Ichi T, Tashiro F, Ikegami H, Yodoi J, Miyazaki JI, (2008). Transgenic expression of antioxidant protein thioredoxin in pancreatic ß cells prevents progression of type 2 diabetes mellitus. Antioxidants & Redox Signaling 10 (1), 43-50.
  • 39. Yoshida T., Takamura H, (2005). The Involvement of Thioredoxin and Thioredoxin Binding Protein-2 on Cellular Proliferation and Aging Process. Annals of the New York Academy of Sciences 1055, 1-12.

Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein

Year 2019, Volume: 2 Issue: 1, 27 - 34, 31.01.2019

Abstract

Morbidite ve mortalite oranları her
geçen gün artan endokrin bir bozukluk olan diabetes mellitus ve tedavisi
üzerine günümüzde oldukça fazla araştırma yapılmaktadır. Ancak hala hastalığın
çeşitli alt tiplerinin oluşum mekanizmaları ve bu mekanizmalara dahil olan
proteinler ile bu proteinlerin sinyal yolakları tam olarak aydınlatılamamıştır.
Tam olarak tedavisi mümkün olmayan bu hastalığın günümüz sedanter yaşam
koşulları ve dengesiz beslenme sonucunda görülme sıklığı gün geçtikçe hızla
artmaktadır. Bu anlamda hastalığın oluşum mekanizmasında etkin rol oynayan
moleküller, proteinler ve bunların yolaklarının aydınlatılması, hastalığın
tedavisinde yeni yaklaşımların oluşması için büyük bir önem arz etmektedir.
Tiyoredoksin etkileşimli protein, son yıllarda keşfedilmiş olup, tip 1 ve tip 2
diabetes mellitusun patoenezinde önemli bir rol oynadığı düşünülmektedir. TXNIP
eksikliği, pankreas beta hücrelerinin canlılığını destekleyerek, tip 1 ve tip 2
diabete karşı korurken, yükselen TXNIP seviyeleri beta hücreli apoptosise neden
olmaktadır.



Bu derlemede diabetes
mellitus ve etiyopatogenezinde önemli bir rolü olan tiyoredoksin protein
hakkında bilgi verilecektir.

References

  • 1. ADA, (2014). Clinical Practice Recommendations. Standards of Medical Care in Diabetes. Diabetes Care 37, 14-80.
  • 2. Alhawiti NM, Mahri SA, Aziz MA, Malik SS, Mohammad S, (2017). TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook. Current Drug Targets 18 (9),1095-1103.
  • 3. Artner I, Hang Y, Mazur M, (2010). MafA and MafB regulate genes critical to-cells in a unique temporal manner. Diabetes 59, 2530-2539.
  • 4. Bodnar JS, Chatterjee A, Castellani LW, (2002). Positional cloning of the combined hyperlipidemia gene Hyplip1. Nature Genetics 30, 110–116.
  • 5. Chen J, Fontes G, Saxena G, Poitout V, Shalev A, (2010). Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated -cell death. Diabetes 59, 440-447.
  • 6. Chen J, Hui ST, Couto FM, (2008). Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic ß cell mass and protects against diabetes. FASEB Journal 22, 3581-3594.
  • 7. Chen J, Jing G, Xu G, Shalev A, (2014). Thioredoxin-Interacting Protein Stimulates its Own Expression via a Positive Feedback Loop. Molecular Endocrinology 28, 674-680.
  • 8. Chen KS, DeLuca HF, (1994). Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochimica et Biophysica Acta 3, 1219-1226.
  • 9. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, Lee RT, (2010). Deletion of thealpha-arrestin protein Txnip in mice promotes adiposity and adipogenesiswhile preserving insulin sensitivity. Diabetes, 59, 1424-1434.
  • 10. Clee M, Nadler ST, Attie AD, (2005). Genetic and genomic studies of the BTBR ob/ob mouse model of type 2 diabetes. American Journal of Therapeutics 12, 491-498.
  • 11. Courboulin A, Paulin R, Giguère NJ, (2011). Role for miR-204 in human pulmonary arterial hypertension. Journal of Experimental Medicine 208, 535-548.
  • 12. Gül K, (2015). Diabetes mellitus sınıflama, tanı ve tarama testlerine genel bir bakış. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 10 (2), 12-16.
  • 13. IDF (International Diabetes Federation), (2013). Diabetes Atlas, 6th edition,
  • 14. Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A, (2014). Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through MIR-124A and FOXA2. Journal of Biological Chemistry 289, 11807-11815.
  • 15. Kibbe C, Chen J, Xu G, Jing G, Shalev A, (2013). FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic ß cells. Journal of Biological Chemistry 288, 23194-23202.
  • 16. Kumar V, Abbas AK, Aster JC, (2013). Robbins basic pathology (Robbins temel patoloji). Çeviren: Tuzlalı S, Güllüoğlu M, Çevikbaş U. Nobel Tıp Kitapevi, İstanbul.
  • 17. Minn A H, Hafele C, Shalev A, (2005). Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces ß-cell apoptosis. Endocrinology 146 (5), 2397-2405.
  • 18. Murray RK, Granner DK, Mayes PA, Rodewell VW, (2014). Harper’s Biochemistry. Çevirenler: Dikmen N, Özgüven T. Nobel Tıp Kitapevleri, Ankara.
  • 19. Oğuz A, (2016). Gestasyonel Diyabet. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 11 (1), 26-29.
  • 20. Özdemir İ, Hocaoğlu Ç, (2009). Tip 2 diabetes mellitus ve yaşam kalitesi: Bir gözden geçirme. Göztepe Tıp Dergisi 24 (2), 73-78.
  • 21. Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P, Jensen CB, (2007). TXNIP regulates peripheral glucose metabolism in humans. PLoS medicine 4 (5), e158.
  • 22. Patwari P, Chutkow W A, Cummings K, Verstraeten V L, Lammerding J, Schreiter E R, Lee R T, (2009). Thioredoxin-independent regulation of metabolism by the -arrestin proteins. Journal of Biological Chemistry 284 (37), 24996-25003.
  • 23. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT, (2006). The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. Journal of Biological Chemistry 281 (31), 21884-91.
  • 24. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S, (2011). Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. American Journal of Physiology-Heart and Circulatory Physiology 301, H1798-H1809.
  • 25. Reich E, Tamary A, Sionov RV, Melloul D, (2012). Involvement of thioredoxin- interacting protein (TXNIP) in glucocorticoid-mediated ß cell death. Diabetologia 55, 1048-1057.
  • 26. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J, (2013). Twelve-year trends in the prevalence and risk factors of diabetes and pre-diabetes in Turkish adults. European Journal of Epidemiology 28, 169-80.
  • 27. Saxena G, Chen J, Shalev A, (2010). Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. Journal of Biological Chemistry 285, 3997-4005.
  • 28. Shalev A, (2014). Minireview: Thioredoxin-Interacting Protein: Regulation and Function in the Pancreatic ß-Cell. Molecular Endocrinology 28, 1211-1220.
  • 29. Shalev A, Pise-Masison CA, Radonovich M, (2002). Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGF-ß signaling pathway. Endocrinology. 143, 3695-3698.
  • 30. Sönmez A, Kutlu M, (2010). Gestasyonel Diyabet Güncel Tarama ve Tanı Yöntemleri. Türkiye Klinikleri Endocrinology-Special Topics 3 (1), 1-5.
  • 31. Spindel ON, World C, Berk BC, (2012). Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxidants & Redox Signaling Journal 16, 587–596.
  • 32. Türkiye Endokrinoloji ve Metabolizma Derneği, (2018). Diabetes Mellitus Ve Komplikasyonlarının Tanı, Tedavi Ve İzlem Kılavuzu. Ankara, Tuna Matbaacılık, 8-11.
  • 33. Vila G, Gessl A W, Riedl M, Luger A, (2016). Other specific types of diabetes. Wiener klinische Wochenschrift 128, 208-211.
  • 34. Westermark P, Andersson A, Westermark GT, (2011). Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews 91, 795-826.
  • 35. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Kahn B. B, (2013). AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Molecular cell 49 (6), 1167-1175.
  • 36. Xu G, Chen J, Jing G, Shalev A, (2012). Preventing ß cell loss and diabetes with calcium channel blockers. Diabetes 61, 848-856.
  • 37. Xu G, Chen J, Jing G, Shalev A, (2013). Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nature Medicine 19, 1141-1146.
  • 38. Yamamoto M, Yamato E, Shu-Ichi T, Tashiro F, Ikegami H, Yodoi J, Miyazaki JI, (2008). Transgenic expression of antioxidant protein thioredoxin in pancreatic ß cells prevents progression of type 2 diabetes mellitus. Antioxidants & Redox Signaling 10 (1), 43-50.
  • 39. Yoshida T., Takamura H, (2005). The Involvement of Thioredoxin and Thioredoxin Binding Protein-2 on Cellular Proliferation and Aging Process. Annals of the New York Academy of Sciences 1055, 1-12.
There are 39 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Hale Ergin Eğritağ 0000-0003-4240-4698

Gizem Koramaz This is me

Publication Date January 31, 2019
Submission Date December 10, 2018
Published in Issue Year 2019 Volume: 2 Issue: 1

Cite

APA Ergin Eğritağ, H., & Koramaz, G. (2019). Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein. Avrasya Sağlık Bilimleri Dergisi, 2(1), 27-34.
AMA Ergin Eğritağ H, Koramaz G. Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein. EurasianJHS. January 2019;2(1):27-34.
Chicago Ergin Eğritağ, Hale, and Gizem Koramaz. “Diabetes Mellitus Ve Tiyoredoksin Etkileşimli Protein”. Avrasya Sağlık Bilimleri Dergisi 2, no. 1 (January 2019): 27-34.
EndNote Ergin Eğritağ H, Koramaz G (January 1, 2019) Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein. Avrasya Sağlık Bilimleri Dergisi 2 1 27–34.
IEEE H. Ergin Eğritağ and G. Koramaz, “Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein”, EurasianJHS, vol. 2, no. 1, pp. 27–34, 2019.
ISNAD Ergin Eğritağ, Hale - Koramaz, Gizem. “Diabetes Mellitus Ve Tiyoredoksin Etkileşimli Protein”. Avrasya Sağlık Bilimleri Dergisi 2/1 (January 2019), 27-34.
JAMA Ergin Eğritağ H, Koramaz G. Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein. EurasianJHS. 2019;2:27–34.
MLA Ergin Eğritağ, Hale and Gizem Koramaz. “Diabetes Mellitus Ve Tiyoredoksin Etkileşimli Protein”. Avrasya Sağlık Bilimleri Dergisi, vol. 2, no. 1, 2019, pp. 27-34.
Vancouver Ergin Eğritağ H, Koramaz G. Diabetes Mellitus ve Tiyoredoksin Etkileşimli Protein. EurasianJHS. 2019;2(1):27-34.